Kalvista Pharmaceuticals (NASDAQ:KALV) released its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.22, MarketWatch Earnings reports. Kalvista Pharmaceuticals had a negative net margin of 84.47% and a negative return on equity of 29.46%.
KALV opened at $31.10 on Friday. Kalvista Pharmaceuticals has a 1-year low of $7.73 and a 1-year high of $34.92. The firm has a market capitalization of $411.35 million, a price-to-earnings ratio of -20.33 and a beta of 2.45.
KALV has been the subject of a number of analyst reports. BidaskClub raised shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. Zacks Investment Research raised shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 target price for the company in a research note on Wednesday, January 2nd. ValuEngine raised shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. Cantor Fitzgerald reissued a “buy” rating and set a $32.00 target price on shares of Kalvista Pharmaceuticals in a research note on Friday, December 14th. Finally, TheStreet raised shares of Kalvista Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Thursday, December 20th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Kalvista Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $27.00.
In other Kalvista Pharmaceuticals news, insider Edward P. Feener sold 4,000 shares of Kalvista Pharmaceuticals stock in a transaction on Wednesday, January 16th. The shares were sold at an average price of $19.55, for a total value of $78,200.00. Following the completion of the sale, the insider now directly owns 106,334 shares of the company’s stock, valued at $2,078,829.70. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Thomas Andrew Crockett sold 10,000 shares of Kalvista Pharmaceuticals stock in a transaction on Monday, January 14th. The shares were sold at an average price of $19.33, for a total transaction of $193,300.00. Following the completion of the sale, the chief executive officer now directly owns 272,411 shares of the company’s stock, valued at $5,265,704.63. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 314,718 shares of company stock valued at $6,509,410. Insiders own 38.40% of the company’s stock.
An institutional investor recently raised its position in Kalvista Pharmaceuticals stock. Geode Capital Management LLC grew its holdings in shares of Kalvista Pharmaceuticals Inc (NASDAQ:KALV) by 30.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 83,881 shares of the specialty pharmaceutical company’s stock after buying an additional 19,636 shares during the quarter. Geode Capital Management LLC owned 0.49% of Kalvista Pharmaceuticals worth $1,656,000 at the end of the most recent reporting period. 77.31% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Kalvista Pharmaceuticals (KALV) Releases Quarterly Earnings Results, Beats Estimates By $0.22 EPS” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.thelincolnianonline.com/2019/03/15/kalvista-pharmaceuticals-kalv-releases-quarterly-earnings-results-beats-estimates-by-0-22-eps.html.
Kalvista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Further Reading: What is insider trading?
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.